The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
Rheumatoid arthritis (RA) is an immune-mediated inflammatory (autoimmune) rheumatic disease of unknown etiology, which is characterized by chronic erosive arthritis (synovitis) and systemic damage of internal organs and leads to early disability and shorter life expectancy in patients. Much attenti...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2019-11-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2780 |
| Summary: | Rheumatoid arthritis (RA) is an immune-mediated inflammatory (autoimmune) rheumatic disease of unknown etiology, which is characterized by chronic erosive arthritis (synovitis) and systemic damage of internal organs and leads to early disability and shorter life expectancy in patients. Much attention is paid to studying the role of interleukin 6 (IL6) in the spectrum of proinflammatory cytokines involved in the pathogenesis of RA. The clinical introduction of anti-IL receptor monoclonal antibodies, such as tocilizumab and sarilumab, that inhibit the activity of this cytokine, is an important step in the improvement of RA treatment. The review considers the data from the main randomized controlled trials of the efficacy and safety of sarilumab in RA and discusses the prospects for using the drug to treat this disease. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |